BIOMARIN PHAR. DL-,001 | 71,990 / +0,80% |
Datum/Vrijeme | 22.01. / 16:37 |
Promj. / Promj.(%) | 0,570 / +0,80% |
Potražnja | - |
Ponuda | - |
Otvaranje | 71,030 |
Prethodno zatvaranje | 71,420 |
Najviša cijena | 71,990 |
Najniža | 70,790 |
Volumen [EUR] | 708,000 |
Volumen [Jedinice] | 10 |
Zaključenja cijena | 9 |
ISIN | US09061G1013 |
Simbol | BM8 |
Burza | Stuttgart |
Vrsta | Stock |
Druge burze
Burza | Posljednji | Volumen | |
---|---|---|---|
Lang & Schwa.. | 71,73 | ![]() |
|
NASDAQ | 87,9900 | ![]() |
898.579 |
IEX | 88,01 | ![]() |
47.244 |
Cboe US | 88,15 | ![]() |
28.240 |
Mexico | 1.760,00 | ![]() |
662 |
Vienna Globa.. | 72,06 | ![]() |
248 |
TradeGate | 72,790 | ![]() |
149 |
London Inter.. | 86,80 | ![]() |
127 |
Frankfurt | 70,7600 | ![]() |
17 |
Stuttgart | 71,990 | ![]() |
10 |
Xetra | 72,11 | ![]() |
0 |
Berlin | 71,02 | ![]() |
0 |
München | 71,22 | ![]() |
0 |
Düsseldorf | 72,16 | ![]() |
0 |
gettex | 72,370 | ![]() |
Vijesti
- BioMarin sinks 32% as FDA delays its hemophilia treatment
19.08.2020 / 16:23 - TeleTrader - Nasdaq turns red as pharma stocks fall
28.04.2020 / 16:48 - TeleTrader - BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
12.12.2016 / 14:29 - GlobeNewswire - NICE Recommends BioMarin's Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England
23.11.2015 / 16:59 - GlobeNewswire